ABSTRACT:
Alkaptonuria (AKU) is a rare disorder of autosomal recessive inheritance. It is caused by a mutation in a gene that results in the accumulation of homogentisic acid (HGA). Characteristically, the excess HGA means sufferers pass dark urine, which upon standing turns black. This is a feature present from birth. Over time patients develop other manifestations of AKU, due to deposition of HGA in collagenous tissue namely ochronosis and ochronotic osteoarthropathy. Although this condition does not reduce life expectancy, it significantly affects quality of life. The natural history of this condition is becoming better understood, despite gaps in knowledge. Clinical assessment of the condition has also improved along with the development of a potentially disease-modifying therapy. Furthermore, recent developments in AKU research have led to new understanding of the disease, and further study of the AKU arthropathy has the potential to influence therapy in the management of osteoarthritis.
Cite this article:
Bhawan B. Bhende. Alka Ptonuria Disorder. International Journal of Nursing Education and Research. 2021; 9(3):364-6. doi: 10.52711/2454-2660.2021.00084
Cite(Electronic):
Bhawan B. Bhende. Alka Ptonuria Disorder. International Journal of Nursing Education and Research. 2021; 9(3):364-6. doi: 10.52711/2454-2660.2021.00084 Available on: https://ijneronline.com/AbstractView.aspx?PID=2021-9-3-26
REFERENCES:
1. https://www.healthline.com/health/alkaptonuria#treatment
2. Lindner, Moritz; Bertelmann, Thomas (2014-01-30). "On the ocular findings in ochronosis: a systematic review of literature". BMC Ophthalmology. 14 (1): 12. doi:10.1186/1471-2415-14-12. ISSN 1471-2415. PMC 3915032. PMID 24479547.
3. https://flipper.diff.org/app/items/info/6243
4. ntrone WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Gene Metab. 2011; 103:307-314. http://www.ncbi.nlm.nih.gov/pubmed/21620748
5. Petit SJ, Fisher M, Gallagher JA, Ranganath LR. Cardiovascular manifestations of alkaptonuria. J Inherit Metab Dis. 2011; [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/21506017
6. https://www.google.com/search?rlz=1C1GNAM_en-GBIN688IN688&sxsrf=ALeKk00UZX-XYCZJ17-fPJ3rKPX19iZPEA:1611926312003&q=complications+OF+ALKAPTONURIA&spell=1&sa=X&ved=2ahUKEwjziey5ncHuAhXH4jgGHc8SDyEQBSgAegQIChAw&biw=1366&bih=625
7. Ranganath LR, Jarvis JC, Gallagher JA (May 2013). "Recent advances in management of alkaptonuria (invited review; best practice article)". J. Clin. Pathol. 66 (5): 367–73)
8. Speeckaert R, Van Gele M, Speeckaert MM, Lambert J, van Geel N (July 2014). "The biology of hyperpigmentation syndromes". Pigment Cell Melanoma Res. 27(4): 512–24. doi:10.1111/pcmr.12235. PMID 24612852.
9. Speeckaert R, Van Gele M, Speeckaert MM, Lambert J, van Geel N (July 2014). "The biology of hyperpigmentation syndromes". Pigment Cell Melanoma Res. 27(4): 512–24. doi:10.1111/pcmr.12235. PMID 24612852.
10. Zatkova A (December 2011). "An update on molecular genetics of Alkaptonuria (AKU)". J. Inherit. Metab. Dis. 34 (6): 1127–36. doi:10.1007/s10545-011-9363-z. PMID 21720873